Souhaitez-vous accéder aux communiqués récents ?

Company announcement – No. 68 / 2021 Zealand Pharma to Participate in Jefferies London Healthcare Conference Copenhagen, DK and Boston, MA, U.S. November 12, 2021 – Zealand Pharma A/S (Nasdaq:...

Company announcement – No. 67/ 2021 Interim report for 9M 2021 Zealand Pharma Presents Financial Results for the First Nine Months of 2021; Provides Updates on Commercial Launch and...

Company announcement – No. 66/ 2021 Zealand Pharma and DEKA Research & Development Corp. Announce Collaboration Agreement to Advance Development of Infusion Pump to Be Used with...

Company announcement – No. 65/ 2021 Zealand Pharma Announces First Subject Dosed in Phase 1 Trial of Amylin Analogue ZP8396 for the Treatment of Obesity Preclinical data have shown potent...

Company announcement – No. 64 / 2021 Zealand Pharma Hosts Conference Call on November 11 at 4 pm CET (10 am ET) to Present Third Quarter Results for 2021 Copenhagen, DK and Boston, MA,...

Company announcement – No. 63 / 2021 Zealand Pharma Announces Presentation of Preclinical Data on Amylin Analogue, ZP8396, and Clinical Data on Glucagon-GLP1 Dual-Agonist, BI 456906, at The...

Company announcement – No. 62 / 2021 Total number of shares and voting rights in Zealand Pharma at September 30, 2021 Copenhagen, DK and Boston, MA, September 30, 2021 – Zealand Pharma A/S...

Company announcement – No. 61 / 2021 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons ...

Company announcement – No. 60 / 2021 Zealand Pharma increases its share capital as a consequence of exercise of employee warrants Copenhagen, DK and Boston, MA, U.S. September 10, 2021 – Zealand...

Company announcement – No. 59/ 2021 Zealand Pharma Presents Data at 2021 ESPEN Virtual Congress Demonstrating Dose-dependent Effects of Glepaglutide in Both Small and Large Intestines of Animal...